The dual GLP-1/GIP agonist — same active ingredient as Mounjaro® and Zepbound®. Clinically proven to deliver 20–25% average weight loss.
No commitment · Free consultation with licensed providers
Dual Action
GLP-1 + GIP agonist
Tirzepatide is a groundbreaking dual hormone agonist that targets both GLP-1 and GIP — the two most powerful appetite and metabolism regulators. This synergistic approach produces significantly greater weight loss than single-hormone medications.
Originally developed for type 2 diabetes under the brand name Mounjaro®, tirzepatide earned FDA approval for weight loss as Zepbound® in 2023. Clinical trials demonstrated unprecedented efficacy, with an average of 20–25% body weight reduction.
Our compounded tirzepatide contains the exact same active pharmaceutical ingredient as brand-name versions, prepared by licensed 503(a) compounding pharmacies. You get identical clinical outcomes at a fraction of the brand cost.
Tirzepatide is fundamentally different from semaglutide. While semaglutide targets only GLP-1, tirzepatide activates both GLP-1 and GIP receptors — creating a synergistic effect that produces superior weight loss outcomes.
Combined Effect: Superior weight loss, better metabolic control, and enhanced results versus single-hormone medications.
SURMOUNT clinical trials, published in the New England Journal of Medicine, demonstrated exceptional weight loss efficacy.
20–25%
Average Weight Loss
Highest average among all FDA-approved weight loss medications in clinical trials.
91%
Achieved 5%+ Loss
Nearly all participants achieved clinically meaningful weight loss in their first year.
57%
Achieved 20%+ Loss
Comparable to bariatric surgery outcomes. Highest of any non-surgical option.
Based on SURMOUNT-1 trial results. Individual outcomes vary based on lifestyle, genetics, and consistency.
Gradual escalation over 20+ weeks minimizes side effects while optimizing efficacy and tolerability.
| Week | Weekly Dose | Therapeutic Purpose |
|---|---|---|
| Week 1–4 | 2.5 mg | Initial phase — body adaptation and tolerance assessment |
| Week 5–8 | 5 mg | First escalation — appetite suppression begins |
| Week 9–12 | 7.5 mg | Intermediate dose — therapeutic effects observed |
| Week 13–16 | 10 mg | Standard maintenance — optimal for most patients |
| Week 17–20 | 12.5 mg | Enhanced dose — increased fat loss acceleration |
| Week 21+ | 15 mg | Maximum dose — peak clinical efficacy |
Your provider adjusts the schedule based on your individual response, tolerance, and weight loss goals. Some patients maintain lower doses with excellent results.
Most side effects improve within the first 1–2 weeks as your body adjusts. These are typically signs the medication is working.
Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, difficulty breathing, or severe allergic reactions.
Your provider will conduct thorough screening to ensure tirzepatide is safe for you. Be transparent about your medical history, current medications, and any concerns during your consultation.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Hormone targets | GLP-1 only | GLP-1 + GIP |
| Mechanism | Single receptor | Dual synergistic |
| Average weight loss | 15–20% | 20–25% |
| Achieve 20%+ loss | 30% | 57% |
| Injection frequency | Weekly | Weekly |
| Compounded cost/month | Starting $179 | Starting $259 |
| Time to results | 4–8 weeks | 4–8 weeks |
The bottom line: Tirzepatide produces superior weight loss due to its dual-hormone mechanism. If you're ready for maximum results, tirzepatide is the stronger choice. Semaglutide works well for patients seeking a more affordable entry point.
Identical active ingredient, dramatically lower cost.
Mounjaro (Brand)
$1,000+
Per month without insurance
Diabetes indication pricing
Zepbound (Brand)
$1,000+
Per month without insurance
Weight loss indication pricing
GetSlimRX Compounded
$259
Per month, compounded
Save 75%+
Same active ingredient as brand
Start your tirzepatide journey with a licensed provider. Take our 2-minute assessment and receive a personalized recommendation within 24 hours.